In vitro and in vivo studies in rhabdomyosarcoma and breast cancer reported IGF1R mRNA and protein expression could be used to identify tumors with increased sensitivity to anti-IGF1R therapy. The gene discussed is IGF1R; the disease is rhabdomyosarcoma.